Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interventional, Open-label, Fixed-dose, Long-term Extension Study to Evaluate Safety of Eptinezumab as Preventive Treatment in Patients With Migraine

NCT05064371 is registered in ClinicalTrials.gov with H. Lundbeck A/S as lead sponsor.

NCT NCT05064371
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05064371 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interventional, Open-label, Fixed-dose, Long-term Extension Study to Evaluate Safety of Eptinezumab as Preventive Treatment in Patients With Migraine
Lead sponsor
H. Lundbeck A/S
Phase
Phase 3
Overall status
Completed
Start date
September 21, 2021
Completion date
June 8, 2024
Enrollment
160 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

migraine